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Abstract
Objective: To determine the prevalence and risk factors for Chlamydia trachomatis (CT) infection in pregnant women and
the rate of transmission of CT to infants.
Methods: Pregnant women ($28 weeks gestation) in Vellore, South India were approached for enrollment from April 2009
to January 2010. After informed consent was obtained, women completed a socio-demographic, prenatal, and sexual
history questionnaire. Endocervical samples collected at delivery were examined for CT by a rapid enzyme test and nucleic
acid amplification test (NAAT). Neonatal nasopharyngeal and conjunctival swabs were collected for NAAT testing.
Results: Overall, 1198 women were enrolled and 799 (67%) endocervical samples were collected at birth. Analyses were
completed on 784 participants with available rapid and NAAT results. The mean age of women was 25.8 years (range 18–
39 yrs) and 22% (95% CI: 19.7–24.4%) were primigravida. All women enrolled were married; one reported .one sexual
partner; and six reported prior STI. We found 71 positive rapid CT tests and 1/784 (0.1%; 95% CI: 0–0.38%) true positive CT
infection using NAAT.
Conclusions: To our knowledge, this is the largest study on CT prevalence amongst healthy pregnant mothers in southern
India, and it documents a very low prevalence with NAAT. Many false positive results were noted using the rapid test. These
data suggest that universal CT screening is not indicated in this population.
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Introduction
Chlamydia trachomatis (CT) is one of the most common genital
pathogens worldwide [1]. Strategies to screen, test, diagnose and
treat this curable, yet prevalent and indolent disease have been
adopted in many countries. Disease in women can include severe
outcomes such as pelvic inflammatory disease and infertility. In
addition, neonates of infected women may have increased
morbidity and mortality. Newborn prematurity and low birth
weight is shown to be associated with maternal chlamydia
infection. Notably 50–75% of infants born to infected mothers
become infected at one or more sites including the conjunctiva,
nasopharynx, vagina, and rectum leading to purulent conjuncti-
vitis, pneumonia, and trachoma [2]. Hammerschlag recognized
that the most frequent site of perinatally acquired chlamydia
infection in US neonates is the nasopharynx with rates as high as
70% and that CT pneumonia can occur in 30% of infants with
nasopharyngeal infection [3]. In addition, Rosenman found that of
US infants exposed to CT at birth, 8 to 44% had conjunctivitis,
and 0 to 17% pneumonia [4].
Most epidemiologic data on CT is from industrialized nations;
however, it is important to characterize CT disease from resource
limited regions where most infants are born. Scarce information is
available on laboratory-confirmed incidence and prevalence of
chlamydia infection in otherwise healthy males and females in
India. Furthermore, the available Indian data show a wide
variation in CT prevalence and methods of laboratory confirma-
tion [5–14]. Some studies have found infection rates of Indian
women ranging from 3.3% to 33% depending on the population
sampled [5–14] (Table 1). Most of these studies focus on high risk
groups (female sex workers, STI/infertility patients, and HIV-
positive women) and were limited by small sample sizes [6,7,9–
11,13]. In Tamil Nadu, Joyee et al. found the prevalence of active
genital CT infection in a healthy adult female population by
NAAT of the urine was 1.1% (95% CI: 0.4%–1.8%) [8]. However,
among symptomatic men and women attending a STI clinic, the
prevalence of confirmed CT infection by culture and/or nested
polymerase chain reaction (PCR) detecting major outer mem-
brane protein (MOMP) was 30.8% (95% CI: 23.4–38.6%) [9].
The prevalence of CT in pregnant women in India has been
shown to vary by geographic region. In a study conducted in
Vellore, TN India in 1993, a prevalence of CT in pregnant
women was found to be 3.3% (95% CI: 1.2%–5.4%) using an
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e34794enzyme immunoassay (EIA) which detects the presence of
chlamydia antigen (ChlamydiazymeH kit, AbbottH,USA) [5].
The authors also reported a higher prevalence of CT in rural
women (5.9%) compared to urban women (1.8%) [5]. A 1999
study from New Delhi found the prevalence of CT infection in
mid-pregnancy and at labor using the ChlamydiazymeH test to be
17% and 18.6%, respectively [15]. In addition, the study also
found neonates born to infected mothers experienced purulent
conjunctivitis more frequently than those born to non-infected
mothers, 12.5% versus 2.8% (p=0.04) respectively [15]. Rastogi et
al. also found a CT prevalence of 18.8% (95% CI: 14.76–
22.96%) among 350 pregnant women in New Delhi diagnosed
using PCR and DFA [12]. One concern about comparing these
studies is that the EIA test is estimated to be only 65–70%
sensitive and 90–99% specific compared to nucleic acid
amplification test (NAAT) methods. Thus the EIA estimates
would be expected to underestimate the true prevalence of
infection.
Current obstetric practice in southern India does not include
universal prenatal screening for CT. This practice is based on
evidence from older local data [5]. In contrast, the CDC
recommends that pregnant women in the US be screened for
CT during their first prenatal visit; and women who are at
increased risk for infection (new or multiple sex partners and those
under 25 years of age) should have a repeat screen during the third
trimester [16–17]. This is based on an estimated CT infection rate
of 5% among US women of reproductive age [18]. However,
there are no data on the current CT prevalence among healthy
pregnant women in Vellore, using more sensitive methods such as
NAAT testing.
Furthermore, although there have been only a few studies
documenting prevalence of Chlamydia trachomatis in southern India,
there are no studies documenting the frequency of maternal to
child transmission of CT in the Vellore region. The Alexander et al
study [5] is more than a decade old and only documents the
prevalence of maternal CT infection. In addition, since 1993,
newer techniques for more accurate detection of CT such as
NAAT have evolved and the prevalence of CT may have changed.
The Clearview Chlamydia Test KitH (Inverness, Houston, TX
77038) is one of the few FDA approved rapid diagnostic tests
(RDT) for CT but a wide range of sensitivity (53–73%) and
specificity (68–99%) on endocervical specimens have been
reported when compared to culture or DNA probe assay/NAAT
[19–23]. Newer NAAT technology using the Roche AmplicorH
CT/NG test (Roche Molecular Systems, Inc., Branchburg, NJ
08876) shows higher sensitivity of 93.3% and specificity of 99.7%
on endocervical specimens compared to cell culture and RDT
[24].
In order to provide data for development of evidence-based
guidelines for resource-limited regions, the objectives of our study
were to determine the prevalence of CT genital infection in
delivering women using highly sensitive NAAT testing and to
study the maternal to child transmission of CT in Vellore, India.
Specific Aims of Study
We aimed 1) to estimate the prevalence of genital CT infection
among women presenting for delivery at Christian Medical
College Hospital (CMCH) Vellore, India using a NAAT technique
2) to identify risk factors associated with chlamydia infections in
pregnant and delivering women in order to guide development of
screening policies if needed; and 3) to estimate the prevalence of
CT infection at birth and to identify factors associated with
maternal-infant transmission.
Methods
Ethics Statement
The institutional review boards at both Cincinnati Children’s
Hospital Medical Center (CCHMC) and the Christian Medical
College Hospital approved the study protocol. Written informed
consent was obtained during enrollment for the subject and her
neonate. All clinical investigation was conducted according to the
principles expressed in the Declaration of Helsinki.
Study Design
This was a prospective hospital-based observational study.
Surveillance Area
CMCH, located in Vellore, India served as the surveillance site
for this study. Vellore is a city in the Indian state of Tamil Nadu
located in tropical southern India midway between the cities of
Chennai (formerly Madras) and Bengaluru (formerly Bangalore).
Vellore town has a population of 177,230 (2001 Indian census) of
which 50.4% are female. CMCH is a private, non-profit, 2000+
bed tertiary referral hospital with primary care clinics (including
pediatrics) and serves a diverse population of lower to middle class
patients. The CMCH obstetrics department reports over 8,000
deliveries per year.
Study Population
From April 2009 to January 2010, delivering women were
approached and recruited daily by a research staff member during
an antenatal outpatient visit, a scheduled labor/induction, or in
the postpartum ward. During the antenatal outpatient visit, a
physician would send his/her patient, based on the study’s
inclusion criteria, to the designated research office for the research
assistant to discuss the study with the delivering woman. On the
inpatient setting, the research assistant approached subjects daily
on the obstetric wards that met inclusion criteria. After the
research assistant obtained the subject’s consent to the study, a
questionnaire on socio-demographic factors, prenatal history, and
sexual history was administered by the research assistant on initial
encounter during a private interview using a pen and paper
format.
Enrollment Criteria
The inclusion criteria required that study participants be 18 to
45 years of age; greater or equal to 28 weeks gestation; and
planning to deliver at CMCH and use the CMCH Vaccine or
Child Health clinic for infant care. Pregnant mothers who had a
history of chronic disease including diabetes, congestive heart
failure, and renal failure were excluded. Stillborn infants and
infants with congenital disorders or malformations were excluded.
Specimen Collection and Laboratory Testing
Endocervical swabs were collected by physicians or a research
assistant during a pelvic exam performed either during an
antenatal outpatient visit; prior to a scheduled labor/induction;
or in the postpartum ward. The first swab was used to perform the
rapid diagnostic test (RDT) and the second for NAAT testing. A
third swab was stored frozen at 270uC for future testing. Swabs
were collected before use of lubricant or insertion of a
prostaglandin tablet for induction to prevent the possibility of
inhibition of the test.
Within 48 hours after delivery, neonatal participant data was
recorded by the research assistant and a conjunctival swab from
the eye and a nasopharyngeal (NP) swab were collected. Swabs
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a positive test would represent contamination by maternal
secretions. After collection, the swabs were stored in a freezer at
270uC for NAAT testing.
Lab Methods
Rapid Test. The RDT used in the study was the Clearview
Chlamydia Test KitH (Inverness, Houston, TX 77038). This test is
a one step immunochromatographic assay for direct antigen
detection with an internal positive control indicator. The test was
performed in the onsite research lab by study staff according to the
package insert instructions.
NAAT. Endocervical specimens were stored in a freezer at
CMCH at 270uC. The NAAT samples were tested at Y.R.
Gaitonade Centre for AIDS Research and Education Laboratory
in Chennai, India using the Roche AmplicorH CT/NG test for
Chlamydia trachomatis (Roche Molecular Systems, Inc., Branchburg,
NJ 08876). The test was performed according to the package insert
instructions. Internal positive controls all tested positive. In
addition, blinded commercial positive controls (n=5) (AccurunH
341, SeraCare Life Sciences, Inc., Milford, MA 01757) were
included among the participant samples sent to the lab. All of these
blinded positive controls were reported as positive results.
In addition, 102 samples from vials with remaining endocervical
swab specimen had DNA extracted using the QIAamp DNA
MinikitH (Qiagen, Hilden, Germany). These extracted samples
were shipped, on dry ice, and retested independently in an
established US laboratory using the Roche Amplicor PCRH
(Roche Diagnostic Systems, Inc., Branchburg, N.J).
Treatment
Subjects’ positive rapid test results were reported to the
attending physicians in both the obstetric and neonatology
departments following birth. Treatment decisions were made by
the primary physicians.
Statistical Methods
Sample size calculation. For sample size estimations, we
used estimated prevalence of CT from previous studies (Table 1).
It was assumed, from these studies, that the prevalence in our
study population is about 3.3%. Using standard sample size
calculations, a sample of 799 is sufficient to detect prevalence up to
9% with precision of 2%. For the neonate samples, a sample of
195 provides 80% power to detect a prevalence of 3% with
precision of 2.5%.
Statistical analysis. Data were analyzed using Statistical
Analysis Systems software (SAS Institute, Cary, NC, Version 9.2).
Means and standard deviations were used to characterize normally
distributed data. T-tests were used to compare means of normally
distributed data. Chi-square and Fisher’s exact tests were used to
assess differences in proportions. All reported P values were 2-
sided and p values ,0.05 were considered statistically significant.
Concordance between the rapid test and NAAT was determined
by the Kappa statistic and Kendall’s Tau B.
Results
Prevalence in Pregnant Women
From April 2009 to January 2010, 7955 women delivered
during the recruitment period. Of these 7955 women, a
convenience sample of 1367 (17%) pregnant and delivering
women was approached for recruitment into the study. Of those,
1198 (88%) women were enrolled; 45% during an antenatal
outpatient visit, 55% before a scheduled labor/induction, and
,1% in the postpartum ward. Figure 1 shows the study flow
diagram.
From the initial 1367 participants approached, 169 delivering
women were not enrolled. Of these, 131 women were not enrolled
in the study after refusing consent or not planning on follow up
care at CMC. Another 38 women did not participate in the study
for other reasons. Inquiries were made to determine the reasons
for declining; 85% indicated they declined because their family did
not want them to participate. Overall, women who declined were
similar to the women who did participate in the study in regards to
urban/rural residence (p=0.77), religion (p=0.47), and gravida
(p=0.1).
Table 2 outlines the demographic characteristics of the enrolled
study participants. The mean age of mothers was 25.6 years and
22% (95% CI: 19.7–24.4%) were primigravida. Mean income was
5064 Rupees/month and 50% of mothers had at least a secondary
education or higher. The predominant religion of enrolled women
was Hinduism which is a reflection of the population composition
in Vellore, India. Urban and village residents were of equal
distribution. All women enrolled were married; one reported
.one sexual partner; and six reported prior STI.
We collected 799 endocervical samples from the 1198 enrolled
subjects and data on 784 participants with both RDT and NAAT
results are reported. 399 enrolled participants (33%) did not have
endocervical samples collected after enrollment; see figure 1 for
reasons. Tested mothers were significantly older, multiparous, and
in the higher socio-economic group compared to untested mothers
(p=0.03, p=,0.0001, and p=0.03; respectively). Please see
table 2. All other demographic were similar. Fifteen (2%)
endocervical samples were lost in processing after collection.
NAAT Versus Rapid Test
The prevalence detected using the NAAT (considered the gold
standard for this study) was 0.1% (95% CI: 0–0.38%). The mother
with the positive NAAT specimen had no significant character-
istics or risk factors. All 71 RDT samples that were positive were
considered to be false positives. Thus, compared to NAAT this
RDT had a sensitivity of 0%, a specificity of 90%. As anticipated,
the statistical analysis by Kappa and Kendall Tau B revealed no
agreement between the RDT and NAAT (Table 3). The samples
retested independently in an established laboratory confirmed the
data found in India, including confirming the single positive. Both
sets of laboratories confirmed that there is a low incidence of CT
in this population of India.
Neonatal Data
There were 811 neonates enrolled which included 12 twin
infants. There were 768 newborn specimens (NP and conjunctival)
obtained from the neonates of the 784 enrolled mothers who had
both NAAT and RDT results reported. During neonatal swab
collection, there were 10 neonates who were lost to follow-up due
to early discharge, 1 mother refused swab collection from her
infant after delivery, and 5 neonates had incomplete swab
collections. The neonatal characteristics included 52% born by
normal vaginal delivery; mean gestation was 39 weeks, and mean
birth weight was 2.99 kilograms (not including twins). Please see
Table 4. Only 11% of neonates had newborn problems which
included neonatal intensive care admission for risk of sepsis;
prematurity, respiratory distress syndrome, gestational diabetes.
We expected to have minimal transmission to the neonate since
only one mother tested positive by NAAT. Because there was such
a low prevalence of mothers with NAAT positive results; we
decided to test only 25% of all neonatal samples collected which
accounted for 195 samples. All neonatal NAAT specimens,
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infant of the mother with the positive endocervical NAAT result.
The neonate born to the NAAT positive mother did not have any
neonatal problems.
Discussion
This is the largest report from India on Chlamydia trachomatis
infection in healthy pregnant women in a non-urban setting using
Figure 1. Study Flow Chart. April 2009 to January 2010, 7955 women delivered during the recruitment period. 1198 (88%) women were enrolled;
799 endocervical samples from the 1198 enrolled subjects were collected and data on 784 participants with both RDT and NAAT results are reported.
doi:10.1371/journal.pone.0034794.g001
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PLoS ONE | www.plosone.org 5 May 2012 | Volume 7 | Issue 5 | e34794NAAT technique. Previous studies have shown the reported
chlamydial infection rates in India have ranged as high as 33% to
as low as 3.3% [5–14] (Table 1). Most of these studies however
have focused on high risk population groups in urban settings,
potentially could have underestimated prevalence compared to
more sensitive NAAT testing [5,8,10,11,14]. Previous studies in
normal pregnant women showed a lower range of infection (3.3–
18.8%) using EIA. We used NAAT for confirmatory testing and
showed the prevalence of genital chlamydia infections amongst
pregnant women to be 0.1% (95% CI: 0–0.38%). Based on this
low prevalence it appears that routine prenatal screening in
southern India does not appear to be indicated.
In our study, we found that 10% of specimens were positive
when evaluated by RDT. We chose the Clearview Chlamydia
Test KitH because it is one of the few FDA approved RDT for CT,
and it had reasonable reported sensitivity (53–73%) and specificity
(68–99%) on endocervical specimens when compared to culture or
DNA probe assay/NAAT [19,20,22,23]. However, in our low
prevalence setting the sensitivity and specificity were lower (0%
sensitive and 90% specific) and there was a major discrepancy
between the RDT and NAAT results. Other studies have also
noted lower sensitivity and specificity of RDT and EIA when
compared to PCR, especially in low prevalence settings [25,26].
If the true specificity of the RDT is between 68 and 99% [19–
23], we would expect a range of 7 to 356 false positives in a sample
size of 784 subjects from a population with a prevalence of 3.3%.
We observed 71 such results. Similarly, if the true sensitivity is
between 58–78%, it is not surprising that the one true positive case
Table 2. Baseline characteristics of Enrolled Mothers, Enrolled Tested mothers, and Enrolled and not Tested.
Enrolled Mothers Enrolled Tested Enrolled Not Tested
P-Value of Tested
mothers vs.
Untested mothers
N Percent N Percent N Percent
Age Group 1198 783 415 0.03
18–23 years 384 32.05 231 29.50 153 36.87
24–29 years 625 52.17 425 54.28 200 48.19
$30 years 189 15.78 127 16.22 62 14.94
Parity 1198 783 415 ,0.0001
Other 935 78.05 649 82.89 286 68.91
Primigravida 263 21.90 134 17.11 129 31.08
Mother’s Education 1195 780 415 0.08
Illiterate 31 2.59 20 2.56 11 2.65
Primary Education 443 37.07 277 35.51 166 40
Secondary/Tertiary 293 24.52 183 23.46 110 26.51
University Diploma 428 35.82 300 38.46 128 30.84
Income Group* 1121 731 390 0.03
(,5000 Rs/mo) 795 70.92 499 68.26 296 75.9
(5000–10,000 Rs/mo) 229 20.43 162 22.16 67 17.18
(.10,000 Rs/mo) 97 8.65 70 9.58 27 6.92
Residence 1196 781 415 0.86
Village 604 50.50 393 50.32 211 50.84
Urban 592 49.50 388 49.68 204 49.16
Religion 1193 779 414 0.07
Hindu 964 80.80 635 81.51 329 79.47
Muslim 165 13.83 96 12.32 69 16.67
Christian 62 5.20 47 6.03 15 3.62
Jain 2 0.17 1 0.13 1 .24
History of STI 1183 775 408 0.64
No 1147 96.96 751 96.90 396 97.06
Yes 6 0.51 3 0.39 3 .74
Don’t Know 30 2.54 21 2.71 9 2.21
Sexual Partners 1190 775 415 1
Only Husband 1189 99.92 774 99.87 415 100
Others 1 0.08 1 0.13
*(50Rs=1 USD).
This table shows that tested mothers were significantly older, multiparous, and higher socio-economic group compared to untested mothers (p=0.03, p=,0.0001, and
p=0.03; respectively).
doi:10.1371/journal.pone.0034794.t002
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the RDT detects all 15 Chlamydia serovars in addition to
Chlamydia psittaci [27]. However, cross-reactivity is unlikely as the
primary explanation for these results.
In newborns, the CT prevalence was found to be zero.
Therefore, the transmission rate from Chlamydia positive mothers
to infants could not be characterized because we did not have
sufficient power to address this question. Further studies need to be
done on pregnant mothers with a higher prevalence of CT
infection to assess maternal to neonate transmission in this setting.
There are some limitations to our study. First, due to limited
staff, we were only able enroll 17% of delivering women during
our study period. However, 88% of women approached were
enrolled. Second, the project sample population may not represent
the local delivering female population. CMCH is a tertiary, private
hospital and some patients may go to a nearby government
hospital, or deliver at home. In addition, not all endocervical
samples were obtained from recruited participants due to logistical
reasons. Few endocervical specimens (n=2) were also obtained
postpartum which may have changed the RDT sensitivity and/or
specificity. Tested mothers were significantly older, multiparous,
and in the higher socio-economic group versus untested mothers
(p=0.03, p=,0.0001, p=0.03; respectively). One reason for this
finding may be because younger women in the lower socio-
economic group delivered their neonate at home (especially if
primigravida) or at a nearby government hospital.
In summary, we found that CT infection appears to be
relatively rare in women delivering in this private tertiary care
hospital in Vellore, India. We found a prevalence of 0.1% (95%
CI: 0–0.38%) by NAAT which was much lower than that noted in
other international studies including pregnant women [28–31].
However, Joyee et al. [8] found a prevalence of 1.1% (95% CI:
0.4–1.8%) in the healthy female population of Tamil Nadu using
urine NAAT. Their result of a low CT prevalence supports our
findings of a very low rate of CT infection in our similar
population. Furthermore, NAAT proved to be superior in the
diagnosis of CT than the RDT in a low prevalence setting.
The local practice is to not perform prenatal screening in
healthy pregnant women in this population based on evidence
from twenty years ago which used older diagnostic methods. We
conclude that our current study justifies that routine prenatal
screening in this population would not be recommended given the
low prevalence. However, future studies are important to reassess
prevalence as sexual practices may change within this culture.
Outpatient pre-natal testing may provide better information in all
SES strata.
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